HHS eliminates 10,000 health agency positions

Summary

On March 27, 2025, HHS Secretary RFK Jr. announced the elimination of 10,000 positions and consolidation of 28 HHS divisions into 15, with layoff notices issued April 1, 2025. The restructuring cost FDA 3,500 positions, CDC 2,400, NIH 1,200, and CMS 300, leading to immediate disruption of drug reviews, disease surveillance, and research administration.

What happened

RFK Jr. framed the restructuring as part of "Make America Healthy Again," claiming $1.8 billion in annual savings. Termination notices arrived April 1, 2025, with some employees learning of their firing only when badge access was revoked. Human resources teams themselves were gutted, creating chaos in determining who still worked for the agencies. FDA reviewers reported being assigned roughly double workloads after colleagues were terminated. Dr. Peter Marks, FDA's top vaccine official and CBER Director since 2016, resigned effective April 5, 2025, citing Kennedy's promotion of "misinformation and lies" about vaccine safety. States sued, and a judge advanced the lawsuit arguing HHS could not unilaterally restructure statutory agencies without congressional authorization.

Impact on the United States

FDA drug and device review timelines lengthened; CDC disease surveillance capacity reduced; NIH research administration impaired; leadership vacuum at FDA's CBER disrupted vaccine and gene-therapy oversight at a critical time.

Documented effects

1. Mar 2025FDA device and tobacco-product reviewers reported roughly double application workloads as of late March 2025, with experts warning of a higher risk of missed red flags[1]
2. Apr 2025Peter Marks (FDA CBER Director) resigned April 5, 2025, citing Kennedy's preference for "subservient confirmation of his misinformation and lies"[2]
3. Judge advanced states' lawsuit challenging legality of restructuring without congressional approval[3]

Why this is rated critical

Simultaneously eliminated 10,000 positions across FDA, CDC, NIH, and CMS, disrupting statutory drug-review and disease-surveillance functions at systemic scale.

states' lawsuit proceeding; court earlier granted a preliminary injunction against the changes

Corrections & updates [4]

Every change to a fact on this page after publication is logged here, newest first.

1. Sep 29, 2026CorrectedEffect

   The Reuters report (via US News) describes two FDA scientists reviewing medical-device and tobacco-product applications, not drug applications; experts warned of a risk of "missing any red flags." Wording corrected.[1]

   Previously

   FDA reviewers handling double workloads as of late March 2025, risking missed safety signals in drug applications

   Now

   FDA device and tobacco-product reviewers reported roughly double application workloads as of late March 2025, with experts warning of a higher risk of missed red flags

2. Sep 29, 2026UpdatedStatus

   In the 19-state lawsuit in the District of Rhode Island, the court earlier granted a preliminary injunction against the changes and in April 2026 denied the government's motion to dismiss; the case is proceeding. The HHS breakdown of the cuts (FDA 3,500, CDC 2,400, NIH 1,200, CMS 300) is now cited to AP.[3][4]

   Previously

   ongoing

   Now

   ongoing (states' lawsuit proceeding; court earlier granted a preliminary injunction against the changes)

3. Sep 29, 2026ClarifiedSource

   BioPharma Dive and Fierce Healthcare are specialist trade publications (Tier 3, not 2). The BioPharma Dive article was published March 29, 2025; the Fierce Healthcare headline is given in full.[2][3]

4. Sep 29, 2026CorrectedCost estimate

   Set to $0. The earlier $400 million net saving applied an unsourced 50% discount to HHS's own claim of $1.8 billion a year and subtracted a $400 million cost the entry itself said could not be measured; the 10-15 year savings and the $1.5 billion broader cost were projected from those figures. No published figure shows the realized saving after rehiring.

   Previously

   net -$400M so far (gross $400M, saved $800M); 10yr -$2.5B; 15yr -$3.5B; broader $1.5B

   Now

   net $0; 10yr $0; 15yr $0; broader $0

Sources [4]